MSB 10.4% $1.49 mesoblast limited

Ann: COVID ARDS Trial Topline 60-Day Results, page-465

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 83 Posts.
    lightbulb Created with Sketch. 14
    "Because you need to inject early"

    This is a lie, has been demonstrated to you as a lie several times yet you persist. You correctly assert that CHF and CLBP trials show treatment is most effective before final stage disease as the good tissue is permanently replaced with scar tissue. You then incorrectly conflate this with moderate to severe covid-19 patients requiring treatment "early". The trial clearly demonstrates that at the point of needing a ventilator to sustain life this potentially irreversible scarring has not occurred (at least in many of the <65 years population, >65 is still an open question according to the data from this trial, the proposed adjustments to dose aim to change this).

    We may eventually find that the patients still dying have suffered too much scarring and it cannot be reversed, earlier treatment would be an obvious next step for these patients, but that is a whole different trial with a different set of concerns - after we are saving as many as possible based on what we know now.

    "because you need to inject early" and you dare call other posters "simplistic".
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.